{"filing":{"accession_number":"0001104659-26-064754","cik":"0001379006","ticker":"NNVC","company_name":"NANOVIRICIDES, INC.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tm2615268d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/tm2615268d1_8k.htm"},"events":[{"id":9303,"run_id":8160,"accession_number":"0001104659-26-064754","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is \"now entering Phase II clinical trial against Mpox in DRC\" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has \"a clinical site in DRC for treatment of Mpox patients.\" This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":891,"accession_number":"0001104659-26-064754","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is \"now entering Phase II clinical trial against Mpox in DRC\" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has \"a clinical site in DRC for treatment of Mpox patients.\" This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:30:43.066086+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":891,"accession_number":"0001104659-26-064754","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is \"now entering Phase II clinical trial against Mpox in DRC\" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has \"a clinical site in DRC for treatment of Mpox patients.\" This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:30:43.066086+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-05-21"}]}